Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

NCT04781998 on ClinicalTrials.gov · last registry update 2023-08-08

A small phase 4 — 24 participants, against a typical 75. The sponsor logged completion for 21 July 2022. Primary outcome, as filed: The primary endpoint is the number of "completers". liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Anders Fink-Jensen, MD, DMSci
Sponsor type: Other
Enrollment: 24
Started: 2021-07-01
Primary completion: 2022-07-21 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The primary endpoint is the number of "completers"

Conditions studied

Mental Disorder · Metabolic Disturbance · Feasibility · Overweight and Obesity · Liraglutide

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.